CFH and LOC387715/ARMS2 genotypes and antioxidants and zinc therapy for age-related macular degeneration.
EVALUATION OF: Klein ML, Francis PJ, Rosner B et al.: CFH and LOC387715/ARMS2 genotypes and treatment with antioxidants and zinc for age-related macular degeneration. Ophthalmology 115(6), 1019-1025 (2008). The late form of age-related macular degeneration (AMD) is a leading cause of irreversible vision loss in the elderly, with a complex etiology involving genetic and environmental factors. Recently, multiple distinct genetic susceptibility loci for AMD have been identified. Specifically, variations in the Complement Factor H (CFH) gene as well as the LOC387715/ARMS2 gene have been shown to be strongly associated with AMD. The Age-Related Eye Disease Study (AREDS) is a large multicenter, placebo-controlled, randomized clinical trial that showed that a combination of zinc and antioxidants reduced progression to late-stage AMD. In the present study, the authors found that within AREDS there was a significant interaction between zinc and CFH genotypes, indicating that CFH genotypes may be predictive of treatment response to zinc supplementation.
Lee
Aaron Y
AY
Department of Ophthalmology and Visual Sciences, Campus Box 8096, Washington University School of Medicine, 660 S. Euclid Avenue, St. Louis, MO 63110, USA.
Brantley
Milam A
MA